Melanotan I Research Guide: Identity, Receptor Binding, and Evidence

Melanotan I, also called MT-I or afamelanotide when naming the active sequence, sits at the intersection of peptide chemistry, melanocortin receptor research, and pharmaceutical history. That overlap makes precision unusually important. A receptor-binding value is not a functional potency result; Melanotan II is a different cyclic molecule; and approval of a finished implant does not transfer to a research reagent.

Key takeaways

• Melanotan I is the linear acetylated and amidated 13-residue sequence Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2.
• Published radioligand assays support a strong MC1R binding preference, but binding constants do not prove functional agonism at every receptor measured.
• The Sawyer, Hruby, Hadley, and Dorr work belongs to the University of Arizona melanocortin lineage; the linear and cyclic branches should remain distinct.
• Early free-peptide human studies were small. The later afamelanotide evidence base concerns the finished SCENESSE sustained-release implant.
• Same molecule (afamelanotide); categorically distinct regulatory frameworks for SCENESSE and an Apex research-grade chemical reagent.

What Is Melanotan I? Identity, Sequence, and Names

Melanotan I is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). The retained research sequence replaces methionine at position 4 with norleucine and L-phenylalanine at position 7 with D-phenylalanine. It is N-terminally acetylated and C-terminally amidated. Those Nle4 and D-Phe7 substitutions explain why the literature and the Apex material record also call the molecule NDP-MSH. Sawyer and colleagues reported the Nle4,D-Phe7 analogue in 1980 as a potent, long-acting melanotropin in a frog-skin bioassay and in mouse-melanoma adenylate-cyclase and tyrosinase preparations.^[1]

Identity should remain separate from purity and content. A vial name does not disclose counterion, residual water, net peptide content, or the analytical method used. Those are lot-level questions. This distinction also prevents a database mass from being presented as if it were a measured mass-spectrum result.

How Does Melanotan I Bind Melanocortin Receptors?

The human melanocortin receptor family includes five G-protein-coupled receptors. MC1R is strongly associated with melanocytic signaling, while MC3R, MC4R, and MC5R participate in other physiological systems. Receptor cloning established this family framework,^[2] but it does not assign every functional effect of an analogue.

In both published characterisation studies, the radioligand was the iodinated form of this molecule, [125I][Nle4,D-Phe7]alpha-MSH, used against cloned MC1R, MC3R, and MC5R and against human MC4R, each expressed in COS cells. It bound a single saturable site at every subtype tested, with the tightest affinity at MC1R.^[3][4] These values support the phrase MC1R-preferring binding. They do not justify calling the compound exclusive to one receptor, and they do not establish functional agonist potency at every subtype.

Saturation-binding limit: these Kd values describe the iodinated tracer [125I][Nle4,D-Phe7]alpha-MSH in heterologous COS-cell expression. They are not functional potency values and are not measured affinities of unlabeled material.

The broader MC1R review literature supplies downstream signaling context rather than a Melanotan I result.^[5] MC1R agonism is directly supported: a cryo-EM structure of the human MC1R-Gs complex was solved with afamelanotide bound,^[6] and FDA labeling for SCENESSE calls afamelanotide a melanocortin 1 receptor agonist that binds predominantly to MC1-R. A structure and a label describe binding geometry and regulatory characterisation, not tissue-level behaviour. For other subtypes, a functional claim needs a matched signaling assay with the exact ligand, receptor construct, cell system, and endpoint. Binding preference and functional selectivity are separate experimental questions.

Where Did Melanotan I Originate? The Arizona Research Lineage

The Melanotan program traces to melanocortin chemistry developed by Victor Hruby, Mac Hadley, Tom Sawyer, and colleagues associated with the University of Arizona College of Medicine. The 1980 paper introduced the linear Nle4,D-Phe7-alpha-MSH analogue.^[1] A 1982 PNAS paper then reported a cyclic alpha-MSH superagonist, representing a distinct structural branch rather than the origin of the linear sequence.^[7]

Hadley, Hruby, Blanchard, and Dorr reviewed the discovery and development of Melanotan I and II in 1998,^[8] and Hadley and Dorr later summarized clinical milestones and commercialization history.^[9] That later record also separates the PT-141 branch from Melanotan I, naming Palatin Technologies alongside the analogue. The licensing and development history of bremelanotide is covered in the PT-141 guide.

This attribution matters because the phrase “Melanotan research” can obscure separate molecules and programs. The correct lineage credits the Arizona team while preserving the difference between MT-I, MT-II, and the later bremelanotide pathway. It also avoids assigning a University affiliation to an abstract that does not print one; the institutional attribution comes from the later review record and author affiliations.

How Is Melanotan I Different from Melanotan II?

The common search phrase “melanotan 1 vs 2” is an identity comparison, not shorthand for interchangeable forms. Melanotan I is a linear 13-residue alpha-MSH analogue. Melanotan II is a cyclic lactam heptapeptide with CAS 121062-08-6, PubChem CID 92432, and an average molecular mass around 1024.2 g/mol. The shorter cyclic topology changes identity, receptor pharmacology, disposition, and the body of evidence that can be cited.

Topology

Melanotan ILinear, 13 residues

Melanotan IICyclic lactam, 7 residues

Sequence family

Melanotan INle4,D-Phe7 alpha-MSH analogue

Melanotan IICyclic alpha-MSH fragment analogue

Registry identity

Melanotan ICAS 75921-69-6; C78H111N21O19; 1646.85 g/mol

Melanotan IICAS 121062-08-6; C50H69N15O9; about 1024.2 g/mol

Receptor evidence

Melanotan ISubtype binding plus direct MC1R structural and label support

Melanotan IISeparate cyclic-ligand pharmacology; not transferable to MT-I

Human record

Melanotan ISmall free-peptide studies and afamelanotide implant trials

Melanotan IISeparate small pilot and supply-chain literature

Approved formulation

Melanotan ISCENESSE contains afamelanotide in a finished implant

Melanotan IINo approved pharmaceutical formulation

A three-person Melanotan II pilot reported nausea, somnolence, yawning, and erections after exposure to the cyclic compound.^[10] That record should not be presented as an adverse-event study of Melanotan I. Likewise, analytical studies of products sold as Melanotan II address a different molecular identity and a separate supply-chain problem.^[11] The dedicated Melanotan II research guide owns that molecule’s evidence.

What Does Human Research on Melanotan I Actually Show?

Early Melanotan I studies were small and addressed pigmentation, pharmacokinetics, or tolerability rather than a modern therapeutic program. A randomized study in 28 participants reported induced pigmentation after subcutaneous administration, but the abstract did not provide a usable adverse-event account.^[12] A later seven-person study observed increased pigmentation at three of eight measured sites; its reported eumelanin-to-pheomelanin ratio change had P=.054, which does not cross the conventional .05 threshold.^[13]

A pharmacokinetic study enrolled three participants and reported a subcutaneous beta half-life range of 0.8 to 1.7 hours for free Melanotan I; the peptide was not detected after oral administration under that study’s conditions. Gastrointestinal upset and flushing were described.^[14] These observations are useful historical records, but samples this small cannot estimate event frequency or define a general safety profile.

Modern afamelanotide trials in erythropoietic protoporphyria are stronger clinical evidence for the approved implant context.^[16] The EU trial NCT00979745 (CUV029) enrolled 74 patients and used five implants over nine months; median pain-free direct-sunlight exposure was 6.0 hours with afamelanotide versus 0.8 hours with placebo. The US trial NCT01605136 (CUV039) recorded 93 participants in the registry and 94 randomly assigned in the journal report, used three implants over six months, and reported corresponding medians of 69.4 versus 40.8 hours. The EU and US labels here are derived from each record’s site list, not a registry region field. These findings should not be rewritten as evidence for an unformulated research vial. The molecule may be shared, but delivery system, manufacturing, study population, exposure, endpoint, and oversight are not.

What Is the SCENESSE and Afamelanotide Regulatory Boundary?

SCENESSE is a finished 16 mg afamelanotide implant, equivalent to 18 mg afamelanotide acetate, made by Clinuvel. The European Commission authorized it on December 22, 2014 under exceptional circumstances for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria, under record EMEA/H/C/002548. FDA approved SCENESSE on October 8, 2019 under NDA 210797 to increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria.

The post-authorization record includes a 115-patient longitudinal cohort followed at two porphyria centres^[15] and a regulator-directed clinical-practice cohort of 117 patients. The latter reported more time spent outside, improved quality of life, and less painful phototoxic reactions during treatment, but no significant difference in the number or duration of those reactions; some authors received sponsor support.^[17] These findings remain formulation- and indication-specific. Search terms such as “Melanotan 1 peptide,” “MT-I,” “afamelanotide,” and “SCENESSE” overlap, but a responsible answer must state which material and evidence lane it means.

What Analytical Documentation Can Verify

A Melanotan I lot record should begin with the exact 13-residue sequence and terminal modifications. Reversed-phase HPLC can report chromatographic peak area under one method. Mass spectrometry can support mass identity when the expected charge states, adducts, and material form are declared. Neither technique alone establishes net peptide content, salt form, residual water, endotoxin, sterility, or functional potency.

The published Apex Laboratory report APX-COA-2026-0528-A provides a specific example for the Melanotan I 10 mg configuration and lot APX-2026-0528-A. Its issue date identifies the certificate, not a testing date. Read the stated identity basis, observed ion and charge, chromatographic result, active-content result and acceptance criteria separately. A reference molecular mass is not an observed ion measurement, and a detector-area percentage is not the amount of peptide in a vial. This example does not establish the lot that will be shipped.

An LC-UV-MS/MS study of products sold as Melanotan II found label-to-content differences and unknown impurities in material bought from three online shops.^[11] That supply-chain observation does not describe Melanotan I or any particular supplier. Its transferable lesson is methodological: area purity, total content, and mass identity answer different questions.

Researchers should match the current Melanotan I material record, Certificate of Analysis, sample identifier and supporting analytical detail to the same lot. Read each report date according to its stated meaning. The HPLC purity guide explains area-percent limits, while the lab-verification library provides the broader documentation framework. Because lots change, the product and COA records must be rechecked at the time of review.

What Are the Main Evidence and Interpretation Limits?

The strongest defensible claims are narrow. The sequence and terminal chemistry define molecular identity. Radioligand assays support MC1R-preferring binding. Small historical studies document selected pigmentation, pharmacokinetic, and tolerability observations. Controlled EPP trials support claims about a named sustained-release afamelanotide implant. None of those statements predicts an outcome for every assay, model, formulation, or supplied lot.

Common overreaches include treating Kd as efficacy, treating receptor binding as functional agonism, using Melanotan II adverse events as if they belonged to Melanotan I, and transferring SCENESSE approval to a research material. Another error is using a structural name to imply that salt form, content, or analytical quality has already been measured. Each inference requires its own evidence.

The two receptor-structure papers provide modern context:^[6][18] one visualizes afamelanotide in the human MC1R-Gs complex, while the other resolves ligand recognition at MC3R and MC5R with different melanocortin ligands. They do not replace the older measured tracer-binding data or create a new lot-specific claim.

References

1. Sawyer TK, et al. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A. 1980;77:5754-8. PMID 6777774.
2. Mountjoy KG, et al. The cloning of a family of genes that encode the melanocortin receptors. Science. 1992;257:1248-51. PMID 1325670.
3. Schiöth HB, et al. Characterisation of melanocortin receptor subtypes by radioligand binding analysis. Eur J Pharmacol. 1995;288:311-7. PMID 7774675.
4. Schiöth HB, et al. Characterisation of the melanocortin 4 receptor by radioligand binding. Pharmacol Toxicol. 1996;79:161-5. PMID 8884876.
5. Herraiz C, et al. MC1R signaling. Intracellular partners and pathophysiological implications. Biochim Biophys Acta Mol Basis Dis. 2017;1863:2448-2461. PMID 28259754.
6. Ma S, et al. Structural mechanism of calcium-mediated hormone recognition and Gβ interaction by the human melanocortin-1 receptor. Cell Res. 2021;31:1061-1071. PMID 34453129.
7. Sawyer TK, et al. [half-Cys4,half-Cys10]-alpha-Melanocyte-stimulating hormone: a cyclic alpha-melanotropin exhibiting superagonist biological activity. Proc Natl Acad Sci U S A. 1982;79:1751-5. PMID 6281785.
8. Hadley ME, et al. Discovery and development of novel melanogenic drugs. Melanotan-I and -II. Pharm Biotechnol. 1998;11:575-95. PMID 9760697.
9. Hadley ME, et al. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27:921-30. PMID 16412534.
10. Dorr RT, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58:1777-84. PMID 8637402.
11. Breindahl T, et al. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test Anal. 2015;7:164-72. PMID 24771717.
12. Levine N, et al. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA. 1991;266:2730-6. PMID 1658407.
13. Dorr RT, et al. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. Photochem Photobiol. 2000;72:526-32. PMID 11045725.
14. Ugwu SO, et al. Skin pigmentation and pharmacokinetics of melanotan-I in humans. Biopharm Drug Dispos. 1997;18:259-69. PMID 9113347.
15. Biolcati G, et al. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. 2015;172:1601-1612. PMID 25494545.
16. Langendonk JG, et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015;373:48-59. PMID 26132941.
17. Wensink D, et al. Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice. JAMA Dermatol. 2020;156:570-575. PMID 32186677.
18. Feng W, et al. Structural insights into ligand recognition and subtype selectivity of the human melanocortin-3 and melanocortin-5 receptors. Cell Discov. 2023;9:81. PMID 37524700.

Regulatory records

• European Medicines Agency. SCENESSE EPAR, EMEA/H/C/002548.
• U.S. Food and Drug Administration. SCENESSE NDA 210797 approval letter and prescribing information.

Frequently Asked Questions

Continue Your Research

Use adjacent records to keep separate molecules, formulations, and evidence questions in their correct lanes. The complete Apex Research Library provides the wider index.

Research Use Disclaimer